GlassScriptPhysician profile
John E Safaryn
NPI 1710069174
$1,307.16
in general payments reported to CMS, 2019-2025
17 companies · $626 in 2025
The $626 reported for 2025 was more than what 92% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2023: $98.25 · 2024: $469 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $277.05 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $196.71 | 2023-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $163.15 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $115.57 | 2024-2025 | Voquezna |
| Comsort, INC | $100.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.35 | 2023-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $92.54 | 2024 | Omvoh |
| Ardelyx, INC. | $45.86 | 2023 | Ibsrela |
| Genzyme Corporation | $41.13 | 2023-2025 | |
| Madrigal Pharmaceuticals | $37.56 | 2025 | Rezdiffra |
| Celltrion USA INC. | $34.40 | 2025 | Vegzelma |
| Atricure, INC. | $27.46 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Orphalan INC | $18.43 | 2025 | Cuvrior |
| Qol Medical, LLC | $16.21 | 2024 | Sucraid |
| Shionogi INC | $14.06 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13.86 | 2024 | Eliquis |
| Ipsen Biopharmaceuticals, INC | $13.82 | 2024 | Bylvay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Safaryn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.